The role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment
https://doi.org/10.21518/akh2025-016
Abstract
Chronic venous diseases of the lower extremities, including varicose veins, are one of the most common pathologies in modern society, affecting up to 73% of women and up to 56% of men. Despite significant advances in surgical treatment, the role of conservative therapy in the treatment of this disease does not diminish. The main group of drugs used in the conservative treatment of venous pathology are the so-called phlebotropic drugs, which are a fairly diverse group of medications of both natural and synthetic origin. One of the leading places among phlebotropic drugs is occupied by micronized purified flavonoid fraction, which is a venoactive drug consisting of diosmin 900 mg and flavonoids, in terms of hesperidin 100 mg. The effectiveness of micronized purified flavonoid fraction in relation to venous symptoms, including pain, heaviness, edema, trophic disorders and others has been demonstrated in many studies. When using MPFF, venous trophic ulcers healed faster and more frequently than in the control group without the drug. The drug was effective in patients who received invasive treatment for varicose veins, both sclerotherapy and open and endovascular interventions. The drug also proved itself in patients with various comorbid disorders, such as phlebogonarthrosis. There is a significant amount of data demonstrating the effectiveness of MPFF in pelvic varicose veins. Currently, in addition to the original drug, there are 4 generics on the market, to which, according to the current point of view, the effects proven in the study of the original drug cannot be transferred. However, the drug Detravenol in a comparative study demonstrated the same efficacy and safety profile as the original drug. This gives our patients the opportunity to choose between the original and the reproduced drug.
About the Authors
E. A. Shcheglov
Petrozavodsk State University;
Republican Hospital of Emergency and Emergency Medical Care
Russian Federation
Russian Federation
N. N. Alontseva
Republican Hospital of Emergency and Emergency Medical Care
Russian Federation
Russian Federation
References
1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15(3):175–184. https://doi.org/10.1016/j.annepidem.2004.05.015.
2. Mekky S, Schilling RS, Walford J. Varicose veins in women cotton workers. An epidemiological study in England and Egypt. Br Med J. 1969;2(5657):591–595. https://doi.org/10.1136/bmj.2.5657.591.
3. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974/.
4. Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, Kirienko AI. Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. Eur J Vasc Endovasc Surg. 2017;54(6):752–758. https://doi.org/10.1016/j.ejvs.2017.08.033.
5. Benda C. Bemerkungen zur normalen und pathologischen Histologie der Zwischenzellen des Menschen und der Säugetiere. Archiv f Frauenk u Eugenetik. 1921;(7):30–40.
6. Prerovsky I, Linhart J, Dejdar R, Svejcar J, Kruml J, Vavrejn B. Research on the primary varicose veins and chronic venous insufficiency. Rev Czech Med. 1962;8:171–178. Available at: https://pubmed.ncbi.nlm.nih.gov/13986047.
7. Azevedo I, Texeira AA, Osswald W. Changes induced by ageing and denervation in the canine saphenous vein; a comparison with the human varicose vein. In: Vanhoutte P (ed.). Return circulation and norepinephrine: an update. John Libbey Eurotext, Paris; 1991, pp. 131–137.
8. Pratt GH. Arterial varices; a syndrome. Am J Surg. 1949;77(4):456–460. https://doi.org/10.1016/0002-9610(49)90398-0.
9. Sicard AL. Description de trois espèces nouvelles de Coccinellidae. J Natural History. 1931;7(41):508–510. https://doi.org/10.1080/ 00222933108673339.
10. Dodd H, Cockett FB. The pathology and surgery of the veins of the lower limb. E.&S. Livingstone; 1956. Available at: https://archive.org/details/in.ernet.dli.2015.550448/page/n3/mode/2up.
11. Raffetto JD, Mannello F. Pathophysiology of chronic venous disease. Int Angiol. 2014;33(3):212–221. Available at: https://pubmed.ncbi. nlm.nih.gov/24755829.
12. Шевченко ЮЛ, Стойко ЮМ. Клиническая флебология. М.: ДПК Пресс; 2016.
13. Botashev RN. Varicose veins of the lower extremities: the current state of the problem. Bulletin of Pirogov National Medical & Surgical Center. 2024;19(1):106–109. (In Russ.) https://doi.org/10.25881/20728255_2023_19_1_106.
14. Shcheglov EA, Alontseva NN. Chronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis. Ambulatornaya Khirurgiya. 2022;19(2):111–118. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-2-111-118.
15. Stoyko YuM, Kiriyenko AI, Zatevakhin II, Pokrovskiy AV, Karpenko AA, Zolotukhin IA et al. Russian Clinical Guidelines for the Diagnostics and Treatment of Chronic Venous Diseases. Flebologiya. 2018;12(3):146–240. (In Russ.) https://doi.org/10.17116/flebo20187031146.
16. Dzhenina OV, Lobanov VN, Gordeev BS. Pharmacotherapy of chronic venous insufficiency of the lower extremities. Ambulatornaya Khirurgiya. 2018;(1-2):26–31. (In Russ.) https://doi.org/10.21518/1995-14772018-1-2-26-31.
17. De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024
18. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality oflife in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37:143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.
19. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity oflIfe improvEment with micronized Flavonoids. Angiology. 2002;53(3):245–256. https://doi.org/10.1177/000331970205300301.
20. Wittens C, Davies AH, Bækgaard N, Broholm R, Cavezzi A, Chastanet S et al. Editor’s Choice – Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737. http://doi.org/10.1016/j.ejvs.2015.02.007.
21. Bogachev VYu. Diagnosis and treatment of chronic venous diseases. Ambulatornaya Khirurgiya. 2015;(3-4):6–11. (In Russ.) Available at: https://www.a-surgeon.ru/jour/article/view/14.
22. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198–208. https://doi.org/10.1016/j.ejvs.2005.04.017.
23. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229. https://doi.org/10.1002/14651858.CD003229.pub3.
24. Bogachev VYu, Boldin BV, Turkin PYu, Dzhenina OV, Samenkov AYu. Current indications for phlebotropic therapy and its duration. Ambulatornaya Khirurgiya. 2021;18(1):13–23. (In Russ.) https://doi.org/10.21518/1995-1477-2021-18-1-13-23.
25. Bogachev VYu, Boldin BV, Turkin PYu, Samenkov AYu. Efficacy of micronized purified flavonoid fraction in treatment of chronic venous oedema. Angiology and Vascular Surgery. 2020;26(2):86–92. (In Russ.) https://doi.org/10.33529/ANGIO2020211.
26. Bogachev VYu. Effectiveness of micronized purified flavonoid fraction-based conservative treatment in chronic venous edema. Phlebolymphology. 2020;27(2):70–80. Available at: https://phlebolymphology.org/effectiveness-of-micronizedpurified-flavonoidfraction-based-conservative-treatment-inchronic-venous-edema.
27. Bogachev V, Boldin B, Turkin P, Samenkov A, Dzhenina O. Micronized purified flavonoid fraction-based conservative treatment of chronic venous disease in a real-world setting. Future Cardiol. 2022;18(10):777–785. https://doi.org/10.2217/fca-2022-0026.
28. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.
29. Bogachev VYu, Rodionov SV, Dzhenina OV. Pharmacotherapy of chronic vein diseases. New European guidelines. Ambulatornaya Khirurgiya. 2018;(3-4):12–21. (In Russ.) https://doi.org/10.21518/1995-1477-2018-3-4-12-21.
30. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B, Giannoukas AD, Lugli M, Maleti O, Myers K, Nelzén O, Partsch H, Perrin M. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.
31. Kalinin RE, Suchkov IA, Kamaev AA, Mzhavanadze N. Duration of treatment with phlebotonics in patients with chronic venous disease. Angiology and Vascular Surgery. 2020;26(3):1–7. (In Russ.) https://doi.org/10.33529/ANGIO2020301.
32. de Souza MD, Cyrino FZ, Mayall MR, Virgini-Magalhães CE, Sicuro F, de Carvalho JJ et al. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon® 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology. 2016;3118(1):505–506. https://doi.org/10.1177/0268355514564414.
33. Bogachev VYu, Boldin BV, Lobanov VN. Benefits of micronized purified flavonoid fraction as adjuvant therapy on the inflammatory response after sclerotherapy. Int Angiol. 2018;3718(1):71–78. https://doi.org/10.23736/S0392-9590.17.03868-8.
34. Bogachev VYu, Boldin BV, Turkin PYu. Detralex: Phlebosclerosing treatment. Angiology and Vascular Surgery. 2018;2418(1):102–105. (In Russ.) Available at: http://angiologia.ru/journals/angiolsurgery/2018/1/12.php.
35. Veverkova L, Kalac J, Jedlicka V, Wechsler J. Analysis of surgical procedures on the vena saphena magna in the Czech Republic and an effect Detralex during its stripping. Rozhl Chir. 2005;84(8):410–416. Available at: https://pubmed.ncbi.nlm.nih.gov/16218350.
36. Veverkova L, Jedlicka V, Wechsler J, Kalac J. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006;13(4):195–201. Available at: https://phlebolymphology.org/analysis-of-the-variousprocedures-used-in-great-saphenous-vein-surgery-inthe-czech-republic-andbenefit-of-daflon-500-mg-topostoperative-symptoms.
37. Pokrovskiy AV, Savelev VS, Kirienko AI, Bogachev VYu, Zolotukhin IA, Sapelkin SV et al. Surgical intervention in combination with add-on therapy with micronized diosmin in varicose vein disease (results of the Russian clinical multicenter, active-control study DEFANS). Angiology and Vascular Surgery. 2007;13(2):47–55. (In Russ.) Available at: http://www.angiolsurgery.org/magazine/2007/2/6.htm.
38. Saveljev V, Pokrovsky A, Kirienko A, Bogachev VYu, Zolotukhin IA, Sapelkin SV. Striping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology. 2008;15(2):45–51. Available at: https://phlebolymphology.org/stripping-of-the-greatsaphenous-vein-under-micronized-purifiedflavonoid-fractionmpff-protection-results-of-the-russian-multicenter-controlledtrial-defance.
39. Bogachev VYu, Golovanova OV, Kuznetsov AN, Shekoyan LO and the DECISION Study Group. On advisability of perioperative phleboprotection in endovascular treatment oflower in varicose disease: first initial results of the decision study. Angiology and Vascular Surgery. 2012;18(2):90–95. (In Russ.) Available at: http://www.angiolsurgery.org/magazine/2012/2/14.htm.
40. Bogachev V, Golovanova OV, Kuznetsov AN, Sheokyan AO. Can Micronized Purified Flavonoid Fraction (MPFF) improve outcomes oflower extremity varicose vein endovenous treatment? First results from the DECISION study. Phlebolymphology. 2013;20(4):181–187. Available at: https://phlebolymphology.org/can-micronized-purified-flavonoidfraction-mpff-improve-outcomes-of-lower-extremityvaricoseveinendovenous-treatmentfirst-results-from-the-decisionstudy.
41. Bogachev VYu, Boldin BV, Turkin PYu. Perioperative administration of micronized purified flavonoid fraction in endovascular treatment of varicose disease. Angiology and Vascular Surgery. 2019;25(2):88–95. (In Russ.) https://doi.org/10.33529/angio2019214.
42. Karathanos C, Batzalexis K, Nana P, Spanos K, Kouvelos G, Rousas N, Giannoukas A. Prospective comparative study evaluating the role of flavonoids after endovenous thermal ablation. Phlebology. 2021;36(8):026835552110023. https://doi.org/10.1177/02683555211002331.
43. Pittaluga P, Chastanet S. Treatment of varicose veins by ASVAL: results at 10 years. Ann Vasc Surg. 2017;38:10. https://doi.org/10.1016/j.avsg.2016.07.021.
44. Scheglov EA. Phlebotropic drugs in preoperative preparation of patients with a varicose illness and osteoarthrosis of the knee. Surgeon. 2012;(8):64–69. (In Russ.) Available at: https://www.elibrary.ru/sgzzzf.
45. Patel M, Varghese R, Rajarshi M. Case Series Analysis of Chronic Venous Insufficiency Patients to Determine Associated Arthrosis. Indian J Surg. 2023;85(1):106–111. https://doi.org/10.1007/s12262-021-02969-x.
46. Shcheglov EA, Alontseva NN. Chronic vein insufficiency correction in patients with lower extremities varicosity and knee osteoarthritis. Ambulatornaya Khirurgiya. 2022;19(2):111–118. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-2-111-118.
47. Akhmetzianov RV, Bredikhin RA. Modern ideas about pharmacotherapy of pelvic congestion syndrome in women. Ambulatornaya Khirurgiya. 2024;21(2):94–103. (In Russ.) https://doi.org/10.21518/akh2024-039.
48. Gavrilov SG, Moskalenko EP, Karalk AV. The Effectiveness and Safety of the Application of the Microionized Purified Flavonoid Fraction for the Treatment of the Patients Presenting with Concomitant Varicose Veins of the Pelvis and Lower Extremities. Flebologiya. 2018;(3):109–116. (In Russ.) https://doi.org/10.17116/flebo2018123109.
49. Tsukanov YuT, Tsukanov AYu, Levdansky EG. The results of the Application of the Micronized Purified Flavonoid Fraction for the Treatment of Secondary Varicose Veins in the Small Pelvis. Flebologiya. 2015;(3):34–40. https://doi.org/10.17116/flebo20159334-40.
50. Seliverstov EI, Andriiashkin VV, Leont’ev SG, Kirienko AI. Biosimilars analogs of enoxaparin: to what extent is their prescription justified for the treatment of venous thrombosis and pulmonary thromboembolism? Flebologiya. 2013;7(4):57–64. (In Russ.) Available at: https://www.mediasphera.ru/issues/flebologiya/2013/4/031997-6976201349.
51. Shchulkin AV, Filimonova AA. Original and generic drugs: what does the clinician need to know? Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10-2):99–104. (In Russ.) https://doi.org/10.17116/jnevro202112110199.
52. Апханова ТВ, Булатов ВЛ, Вахратьян ПЕ, Волков АМ, Гаврилов ЕК, Головина ВИ и др. Варикозное расширение вен нижних конечностей: клинические рекомендации. 2025. Режим доступа: https://phlebounion.ru/recommendations#popup=/recommendations/varikoznoyerasshireniye-ven-nizhnikh-konechnostey-afr-4-2024-31.
53. Ponomarev EA, Strepetov NN, Sotnikov IE, Vasiliev SV, Arnautov VS, Kasatkina IS, Bukhtenkov AV. Use of Detravenol in treatment of chronic venous insufficiency oflower limbs. Angiology and Vascular Surgery. 2020;26(2):95–102. (In Russ.) https://doi.org/10.33529/ANGIO2020201.
54. Ilyukhin EA, Kurginyan KhM, Kovalenko KE, Norvardyan AM, Abukhamdan AS, Gevorgyan AA, Kartoev IR. Impact of Micronized Purified Flavonoid Fraction on Subjective Symptoms After Endovenous Laser Varicose Vein Surgery: the Protocol of the Randomized Controlled Trial DEMO. Flebologiya. 2023;17(4):338–342. (In Russ.) https://doi.org/10.17116/flebo202317041338.
55. Ilyukhin EA, Kurginyan KhM, Kovalenko KE, Norvardyan AM, Abukhamdan AS, Gevorgyan AA, Kartoev IR. Impact of Micronized Purified Flavonoid Fraction on Venous Symptoms After Endovenous Laser Ablation: a Randomized Controlled Trial DEMO. Flebologiya. 2024;18(2):122–131. (In Russ.) https://doi.org/10.17116/flebo202418021122.
56. Lobastov KV. Letter to the Editor of the journal “Phlebology” regarding the results of two randomized controlled trials “DEMO” and “GOLIATH” published by Ilyukhin E.A. et al. (Flebologiya. 2024;18(2):122–131, 139–152). Flebologiya. 2024;18(4):351–352. (In Russ.) https://doi.org/10.17116/flebo202418041351.
57. Ilyukhin EA, Kurginyan KhM. Authors’ response to Lobastov K.V. regarding the results of two randomized controlled trials “DEMO” and “GOLIATH” published by Ilyukhin E.A. et al. (Flebologiya. 2024;18(2):122–131, 139–152). Flebologiya. 2024;18(4):353–354. (In Russ.) https://doi.org/10.17116/flebo202418041353.
Review
For citations:
Shcheglov E.A., Alontseva N.N. The role of the micronized purified flavonoid fraction drug in lower extremities chronic vein diseases treatment. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2025;22(1):59-69. (In Russ.) https://doi.org/10.21518/akh2025-016
Views:
581
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 